Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.54 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632675 | 0.90 | AR (0.53) | ARSCN8ASCN10AHPGDSSLC6A4 | |
| SCHEMBL16632624 | 0.88 | AR (0.57) | ARHPGDSSLC6A4ACHECA1 | |
| SCHEMBL16640617 | 0.87 | AR (0.59) | ARHPGDSSLC6A4ACHECA1 | |
| SCHEMBL16632331 | 0.86 | SLC6A4 (0.58) | ARHPGDSSLC6A4ACHECA1 | |
| SCHEMBL16632414 | 0.84 | AR (0.53) | ARSCN8ASCN10AHPGDSSLC6A4 | |
| SCHEMBL16632539 | 0.84 | SLC6A4 (0.50) | ARSCN8ASCN10ASLC6A4NR3C1 | |
| SCHEMBL6100395 | 0.83 | HPGDS (0.56) | ARHPGDSSLC6A4ACHECA1 | |
| SCHEMBL16632452 | 0.83 | P4HB (0.39) | ARSLC6A4CA1CA2 | |
| SCHEMBL16640622 | 0.81 | AR (0.54) | ARSCN8ASCN10ASLC6A4ACHE | |
| SCHEMBL16632541 | 0.80 | SLC6A4 (0.57) | ARSCN8ASCN10ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | AR 3070/4885SCN8A 4760/4885SCN10A 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.